Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2025 | The future of ctDNA as a prognostic biomarker in cervical cancer

Jyoti Mayadev • 2 Jun 2025

ASCO 2025

Cervical Cancer Gynecological Cancer

CALLA

Jyoti Mayadev, MD, University of California San Diego Medical Center, San Diego, CA, shares her insights into the future implementation of ultrasensitive circulating tumor DNA (ctDNA) analysis as a tool for biomarker detection in locally advanced cervical cancer (LACC). While the technique shows promise for prognostic and predictive use in informing treatment personalization, its integration into clinical practice and trials remains an ongoing area of development. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.